Cargando…
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors in both preclinical and clinical settings. In light of the recent discovery of tumor-init...
Autores principales: | Fang, Douglas D., Zhang, Cathy C., Gu, Yin, Jani, Jitesh P., Cao, Joan, Tsaparikos, Konstantinos, Yuan, Jing, Thiel, Melissa, Jackson-Fisher, Amy, Zong, Qing, Lappin, Patrick B., Hayashi, Tomoko, Schwab, Richard B., Wong, Anthony, John-Baptiste, Annette, Bagrodia, Shubha, Los, Geritt, Bender, Steve, Christensen, James, VanArsdale, Todd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695076/ https://www.ncbi.nlm.nih.gov/pubmed/23826249 http://dx.doi.org/10.1371/journal.pone.0067258 |
Ejemplares similares
-
Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
por: Langdon, Simon P., et al.
Publicado: (2019) -
Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
por: Shang, Xiaosong, et al.
Publicado: (2022) -
PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
por: Chow, Zeta, et al.
Publicado: (2021) -
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
por: Wainberg, Zev A., et al.
Publicado: (2017) -
Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer
por: Espana-Serrano, Laura, et al.
Publicado: (2016)